Fused Gamma-Carboline Compositions for 5-HT and D2 Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for additional compounds with strong serotonin receptor, serotonin transporter (SERT), and/or dopamine D2 receptor activities to treat conditions such as anxiety, psychosis, schizophrenia, sleep disorders, and other psychiatric and neurological disorders, while minimizing side effects associated with conventional treatments.
Innovation Solution
The development of a compound, referred to as Compound 1, which exhibits potent affinity for serotonin receptors (5-HT2A, 5-HT2B), serotonin transporters (SERT), dopamine receptors (D2), sodium channels, and norepinephrine transporters, available in free or pharmaceutically acceptable salt forms, including sustained or delayed release formulations, and osmotic-controlled release oral delivery systems.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used to treat psychiatric and neurological disorders, then therapeutic effects are achieved, but side effects increase
Solution Approach 1:
The patent modifies the chemical structure of gamma-carboline compounds by introducing specific substituents at defined positions (e.g., R1-R6 groups) to alter pharmacological properties. This structural parameter change enables selective receptor binding with improved therapeutic profile and reduced side effects compared to conventional treatments
Solution Approach 2:
The invention creates composite pharmaceutical formulations combining the novel fused gamma-carboline compound with specific pharmaceutically acceptable carriers and excipients. This composite approach enhances drug delivery, stability, and therapeutic efficacy while minimizing adverse effects
2Duration of action of moving object
If sustained or delayed release formulations are developed, then therapeutic efficacy is enhanced, but device complexity increases
Solution Approach 1:
The patent employs sustained and delayed release formulation strategies that release the active compound periodically over time rather than all at once. This periodic release mechanism maintains therapeutic drug levels in the body for extended periods, reducing dosing frequency while managing formulation complexity through established pharmaceutical technologies
Solution Approach 2:
The invention utilizes porous matrix materials and controlled release delivery systems that provide sustained drug release through diffusion and erosion mechanisms. These porous formulations enable prolonged therapeutic action without requiring complex device structures, leveraging material science principles for controlled release
Data Source
AI summary
The invention relates to pharmaceutical compositions comprising the compound of Formula I,and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine D2 receptor signaling, sodium channel activity, and/or norepinephrine transporter activity.